Alto Neuroscience, Inc. Common Stock (NY:ANRO)

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

February 13, 2026

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

February 03, 2026

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

January 14, 2026

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

January 13, 2026

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

December 03, 2025

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 12, 2025

Alto Neuroscience to Participate in Upcoming Investor Conferences

October 28, 2025

Alto Neuroscience Announces $50 Million Private Placement Financing

October 20, 2025

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

October 20, 2025

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 07, 2025

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

October 03, 2025

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

September 22, 2025

From Grabar Law Office

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

September 19, 2025

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

Topics Fraud Lawsuit

September 19, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

Topics Fraud Lawsuit

September 19, 2025

Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO

September 18, 2025

Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO

Topics Fraud Lawsuit

September 18, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Topics Fraud Lawsuit

September 17, 2025

From Faruqi & Faruqi LLP

ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

September 17, 2025

Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

September 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

Topics Fraud Lawsuit

September 17, 2025

Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

Topics Fraud Lawsuit

September 16, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

Topics Fraud Lawsuit

September 16, 2025

ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO

Topics Fraud Lawsuit

September 15, 2025

From The Rosen Law Firm PA

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

September 15, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

Topics Fraud Lawsuit

September 15, 2025

ALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

Topics Fraud Lawsuit

September 15, 2025

Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO

September 14, 2025

From Pomerantz LLP

ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights

September 13, 2025

From Rosen Law Firm